Conrad Siegel Investment Advisors Inc. Has $235,000 Stock Holdings in Eli Lilly and Company $LLY

Conrad Siegel Investment Advisors Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 301 shares of the company’s stock after selling 28 shares during the quarter. Conrad Siegel Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $235,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in LLY. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department raised its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, TD Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their target price for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $755.32 on Tuesday. The company has a 50 day moving average of $737.49 and a 200 day moving average of $769.01. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $714.88 billion, a P/E ratio of 49.37, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.30.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.